ImmunoScape, a San Diego, CA and Singapore-based pre-clinical biotechnology company, raised $14M in funding.
The round was led by Anzu Partners, with participation from Amgen Ventures and EDBI.
The company intends to use the funds to expedite development efforts and to advance their therapeutic candidates toward the clinic.
Led by CEO Choon Peng Ng, ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company’s proprietary Deep Immunomics technology and machine learning platforms enable sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors.
ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic.